TIDMVAL
ValiRx PLC
19 June 2023
ValiRx PLC
("ValiRx" or the "Company")
Inaphaea BioLabs Operational Update
London, UK - ValiRx Plc (AIM: VAL), a life science company
focusing on early-stage cancer therapeutics and women's health,
announces an operational update from the Company's wholly owned
subsidiary, Inaphaea BioLabs Limited ("Inaphaea").
Inaphaea has entered into an agreement with the Virtual CRO
services company OncoBone Limited ("OncoBone") whereby clients of
OncoBone can access Inaphaea services. OncoBone offers a service to
virtual biotech and other biopharma clients whereby OncoBone
designs and commissions pre-clinical work on behalf of the client.
To conduct the laboratory work, OncoBone engages with a range of
pre-clinical Contract Research Organisations ("CROs") to execute on
the experimental designs that OncoBone has developed. Inaphaea is
now confirmed as an OncoBone supplier of cell-based assays.
Additionally, Inaphaea is pleased to report that the cell-based
assay services are now listed on scientist.com, a database of CROs
that can be used by biotechnology and pharmaceutical companies to
search for scientific capabilities.
Dr Suzy Dilly, CEO at ValiRx explains "This operational update
demonstrates the progress made by Inaphaea towards generating
contract revenues. We're particularly excited by the prospect of
working with OncoBone due to the innovative nature of their Virtual
CRO service."
The Directors of the Company take responsibility for this
announcement.
For more information, please contact:
ValiRx plc Tel: +44 (0) 2476 796496
www.valirx.com
Dr Suzanne Dilly, CEO Suzanne.Dilly@valirx.com
Inaphaea BioLabs Limited www.inaphaea.com
Dr Andrew Carnegie, Head of Strategic Andrew.Carnegie@inaphaea.com
Commercial Development
V Formation (Public Relations) +44 (0) 115 787 0206
www.vformation.biz
Lucy Wharton - Senior PR Executive
Sue Carr - Director lucy@vformation.biz
sue@vformation.biz
------------------------------
Cenkos Securities plc (Joint Broker) Tel: +44 (0) 20 7397
8900
Dale Bellis/Michael Johnson (Sales)
Callum Davidson/Giles Balleny (Corporate
Finance)
------------------------------
Turner Pope Investments (Joint Broker) Tel: +44 (0) 20 3657
James Pope / Andy Thacker 0050
------------------------------
Notes for Editors
About ValiRx
ValiRx is a life science company focused on early-stage cancer
therapeutics and women's health, accelerating the translation of
innovative science into impactful medicines to improve patient
lives.
ValiRx provides the scientific, financial, and commercial
framework for enabling rapid translation of innovative science into
clinical development.
Using its extensive and proven experience in research and drug
development, the team at ValiRx selects and incubates promising
novel drug candidates and guides them through an optimised process
of development, from pre-clinical studies to clinic and
investor-ready assets.
ValiRx connects diverse disciplines across scientific,
technical, and commercial domains, with the aim of achieving a more
streamlined, less costly, drug development process. The team works
closely with carefully selected collaborators and leverages the
combined expertise required for science to advance.
Lead candidates from ValiRx's portfolio are outlicensed or
partnered with investors through ValiRx subsidiary companies for
further clinical development and commercialisation.
ValiRx listed on the AIM Market of the London Stock Exchange in
October 2006 and trades under the ticker symbol: VAL.
For further information, visit: www.valirx.com
About Inaphaea BioLabs
Inaphaea BioLabs is a new pharmaceutical services company, based
in Nottingham (UK), offering cell-based assays specialising in
oncology and women's health. Our aim is to improve the translation
of early drug discovery projects towards the clinic. Driven by a
desire to generate deeper biological understanding of drug
candidates in discovery and preclinical phases of development,
Inaphaea will provide testing services that generate the necessary
data, analysis and insights to aid decision making in translational
drug development.
Spun out from ValiRx PLC, the core team within Inaphaea have a
strong background of preclinical and clinical drug development, and
of understanding both the commercial and scientific needs of the
service users from both sides of the table.
Inaphaea will offer a range of services across all areas of
cell-based assays, including efficacy and selectivity of activity
against cancer cells; mechanistic and binding assays; and
measurements of production of cell markers and hormones. Inaphaea's
services will evolve over time to incorporate new techniques and
technologies with the ambition to improve biological understanding
and translatability of early discovery in drug development.
For further information, visit www.inaphaea.com
About OncoBone
OncoBone offers scientific expertise to pharmaceutical and
biotech industry and their service providers globally. OncoBone
representatives have a long history of working in CRO business and
a large global network of high-quality CRO partners. OncoBone
utilizes this extensive experience to guide pharma/biotech
companies in need of CRO services to work with the best fit CRO
partners. OncoBone can assist its pharma/biotech clients in their
preclinical-stage programs through its Virtual CRO concept, where
OncoBone subcontracts the work to its CRO partners and manages the
projects internally.
About Scientist.com
Scientist.com's mission is to empower and connect scientists
worldwide. The company's digital research platform combines a
custom-built, cloud native technology stack with white-glove
customer and scientific support to enable scientists to run more
innovative experiments in less time and at lower cost.
Scientist.com leverages internally developed machine learning
models to provide actionable insights that improve operational
efficiency and effective research management. Scientist.com
connects the world's top pharmaceutical companies, biotechnology
companies and the US National Institutes of Health (NIH) to the
world's largest network of scientific suppliers.
Visit scientist.com to learn more.
Cautionary statement
Certain statements made in this announcement are forward-looking
statements. Such statements are based on current expectations and
assumptions and are subject to a number of risks and uncertainties
that could cause actual events or results to differ materially from
any expected future events or results expressed or implied in these
forward-looking statements. Persons receiving this announcement
should not place undue reliance on forward-looking statements.
Unless otherwise required by applicable law, regulation or
accounting standard, the Company does not undertake to update or
revise any forward-looking statements, whether as a result of new
information, future developments or otherwise.
This communication is a "Reach" announcement. Reach is a
non-regulatory news service. By using this service an issuer is
confirming that the information contained in this announcement is
of a non-regulatory nature. Information required to be notified
under the AIM Rules for Companies, Market Abuse Regulation or other
regulation would be disseminated as an RNS regulatory announcement
and not on RNS Reach.
This information is provided by Reach, the non-regulatory press
release distribution service of RNS, part of the London Stock
Exchange. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NRAFVLLFXQLBBBX
(END) Dow Jones Newswires
June 19, 2023 02:00 ET (06:00 GMT)
Valirx (LSE:VAL)
Gráfico Histórico do Ativo
De Ago 2024 até Set 2024
Valirx (LSE:VAL)
Gráfico Histórico do Ativo
De Set 2023 até Set 2024